Beam Therapeutics Inc.

21.54-0.8500-3.80%Vol 957.36K1Y Perf -56.61%
Oct 4th, 2023 16:00 DELAYED
BID21.00 ASK22.36
Open22.47 Previous Close22.39
Pre-Market- After-Market21.55
 - -  0.01 0.05%
Target Price
77.67 
Analyst Rating
Moderate Buy 1.57
Potential %
260.59 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     43.94
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.56 
Earnings Rating
Market Cap1.71B 
Earnings Date
6th Nov 2023
Alpha0.01 Standard Deviation0.26
Beta1.57 

Today's Price Range

21.0222.60

52W Range

21.0254.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.71%
1 Month
-4.56%
3 Months
-29.88%
6 Months
-24.28%
1 Year
-56.61%
3 Years
0.67%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BEAM21.54-0.8500-3.80
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
4.60
4.60
0.19
0.24
-1 066.00
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
-
-340.40
-326.40
-
-
RevenueValueIndustryS&P 500US Markets
40.88M
0.58
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-1.38-1.0821.74
Q01 2023-1.36-1.332.21
Q04 2022-1.32-0.5459.09
Q03 2022-1.30-1.56-20.00
Q02 2022-1.08-1.025.56
Q01 2022-1.10-1.018.18
Q04 2021-1.02-0.8516.67
Q03 2021-0.78-0.4246.15
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date6th Nov 2023
Estimated EPS Next Report-1.32
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume957.36K
Shares Outstanding79.20K
Shares Float75.71M
Trades Count14.53K
Dollar Volume20.50M
Avg. Volume896.39K
Avg. Weekly Volume916.96K
Avg. Monthly Volume926.18K
Avg. Quarterly Volume846.02K

Beam Therapeutics Inc. (NASDAQ: BEAM) stock closed at 22.39 per share at the end of the most recent trading day (a 4.14% change compared to the prior day closing price) with a volume of 975.14K shares and market capitalization of 1.71B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 166 people. Beam Therapeutics Inc. CEO is John Evans.

The one-year performance of Beam Therapeutics Inc. stock is -56.61%, while year-to-date (YTD) performance is -42.75%. BEAM stock has a five-year performance of %. Its 52-week range is between 21.02 and 54.3, which gives BEAM stock a 52-week price range ratio of 1.56%

Beam Therapeutics Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 3.98, a price-to-sale (PS) ratio of 66.67, a price to cashflow ratio of 29.90, a PEG ratio of -, a ROA of -25.17%, a ROC of -33.51% and a ROE of -40.23%. The company’s profit margin is -%, its EBITDA margin is -326.40%, and its revenue ttm is $40.88 Million , which makes it $0.58 revenue per share.

Of the last four earnings reports from Beam Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.32 for the next earnings report. Beam Therapeutics Inc.’s next earnings report date is 06th Nov 2023.

The consensus rating of Wall Street analysts for Beam Therapeutics Inc. is Moderate Buy (1.57), with a target price of $77.67, which is +260.59% compared to the current price. The earnings rating for Beam Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Beam Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Beam Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.12, ATR14 : 1.20, CCI20 : -197.38, Chaikin Money Flow : -0.02, MACD : -0.66, Money Flow Index : 24.71, ROC : -10.62, RSI : 38.68, STOCH (14,3) : 27.96, STOCH RSI : 0.47, UO : 46.14, Williams %R : -72.04), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Beam Therapeutics Inc. in the last 12-months were: Amy Simon (Sold 16 099 shares of value $480 843 ), Burrell Terry-Ann (Sold 0 shares of value $-1 332 104 ), Burrell Terry-Ann (Sold 109 325 shares of value $4 858 728 ), Christine Bellon (Sold 2 092 shares of value $61 996 ), Ciaramella Giuseppe (Option Excercise at a value of $54 371), Ciaramella Giuseppe (Sold 57 401 shares of value $2 121 648 ), Evans John (Sold 0 shares of value $-99 997 ), Evans John (Sold 11 654 shares of value $345 311 ), Giuseppe Ciaramella (Option Excercise at a value of $103 084), Giuseppe Ciaramella (Sold 108 416 shares of value $4 299 882 ), John Evans (Sold 11 654 shares of value $345 334 ), Simon Amy (Sold 391 shares of value $11 918 ), Terry-Ann Burrell (Option Excercise at a value of $1 332 104), Terry-Ann Burrell (Sold 109 325 shares of value $4 858 817 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (71.43 %)
10 (71.43 %)
10 (71.43 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (28.57 %)
4 (28.57 %)
4 (28.57 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.57
Strong Buy
1.57
Strong Buy
1.57

Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises of Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.

CEO: John Evans

Telephone: +1 857 327-8775

Address: 26 Landsdowne Street, Cambridge 02139, MA, US

Number of employees: 166

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

56%44%

Bearish Bullish

60%40%

 

News

Stocktwits